logo
Australian Government Doubles Down on Urgent Care Clinics

Australian Government Doubles Down on Urgent Care Clinics

Medscape21-05-2025
The Australian government has bet big on Medicare Urgent Care Clinics (UCCs) and is now winning over some previously skeptical general practitioners (GPs). Still, not everyone is convinced that these clinics will relieve the pressure on emergency departments.
Since 2022, the government has spent hundreds of millions of dollars establishing 87 Medicare UCCs around the country. It is now doubling down on this investment, with 50 more clinics planned.
Medicare UCCs offer free or bulk-billed healthcare services for urgent conditions that are not life-threatening. So far, almost 1.5 million people have visited these centers.
'Medicare UCCs have already delivered significant benefits for Australians through high-quality, accessible, walk-in care,' a spokesperson for the Department of Health, Disability and Ageing told Medscape Medical News .
The Royal Australian College of GPs (RACGP) and the National Council of Primary Care Doctors raised serious concerns about the expansion of the Medicare UCCs before the federal election, arguing that it would be more cost-effective to fund general practices.
RACGP's Stance Softens
Following the Labor Party's landslide victory, however, it's clear that these Medicare UCCs are here to stay. Moreover, they are offering some RACGP members high paying and interesting work.
'GPs working in UCCs report a high level of job satisfaction,' Sneha Wadhwani, MBChB, regional clinical director for New South Wales and head of GP Wellbeing at ForHealth, told Medscape Medical News . ForHealth runs 36 Medicare UCCs and is the largest provider of bulk-billed primary care services in Australia.
Sneha Wadhwani, MBChB
'The 2 PM to 10 PM shifts really suit me because I'm wanting to work in my other role as associate professor [of urgent care] at the University of the Sunshine Coast,' John Adie, MBChB, PhD, clinical director of the South Brisbane Medicare UCC, told Medscape Medical News . Adie's clinic is located within a general practice and is staffed by one primary care physician and one nurse 7 days per week.
Just over half (55%) of presentations at the clinic are for minor infections such as bronchitis or tonsillitis. Around 20% relate to minor injuries, including wounds that can be closed with stitches, glue, or Steri-Strips; fractures; or foreign bodies that can be removed from ears with air suction and from eyes with a slit lamp. 'If you come to us, there's a 97% chance that you will not have to go to the emergency department,' said Adie.
John Adie, MBChB, PhD
As the Medicare UCCs have become more established, the RACGP's stance seems to have softened. 'We value the work that our members are doing in those clinics, and we're keen to support them,' Michael Wright, MBBS, PhD, president of the RACGP, told Medscape Medical News .
Underlying Problems Remain
An interim evaluation published in March showed that Medicare UCCs were performing well, with median waiting times of 14.5 minutes. About 46% of patients avoid an emergency department visit by attending a UCC. But the evaluation also showed room for improvement. 'We're keen to work with the government to address some of the problems that have been identified,' said Wright.
Michael Wright, MBBS, PhD
The Medicare UCCs are substantially cheaper than emergency departments. Each presentation at a UCC costs $246.50 instead of $616 at an emergency department. But this amount is 'more than five times what a GP consult rebate is for a 20-minute consultation,' said Wright.
It is difficult to determine the impact of Medicare UCCs on emergency departments without a more rigorous analysis, Henry Cutler, PhD, professor of health economics and director of the Macquarie University Centre for the Health Economy in Sydney, told Medscape Medical News . 'It needs more of an academic approach to evaluate these programs,' he said.
Henry Cutler, PhD
Medicare UCCs are a 'Band-Aid solution' that does not address the underlying problems that are putting pressure on emergency departments, Charlotte Hespe, MBBS, PhD, the head of General Practice at The University of Notre Dame in Sydney, told Medscape Medical News . The main problem is patients' decision not to see their GP for preventive care and chronic disease management because it is too expensive, she added.
Charlotte Hespe, MBBS, PhD
Bulk-billing rates are declining because government funding has not kept pace with the costs of running a general practice. Relief seems to be on the way, however, with $7.9 billion being allocated toward supporting general practices to bulk bill starting November 1.
Medicare UCCs are offering 'massive hourly rates,' making it 'hard for us to compete for that workforce,' Toby Gardner, MBBS, director of a private UCC in Launceston, told Medscape Medical News . Gardner's clinic lost state government funding after the Medicare UCCs were established. 'It's made it harder for us to remain financially viable,' he said.
Toby Gardner, MBBS
Despite these setbacks, the private clinic has used its relationships with local pathology and x-ray providers to keep patients out of public hospital emergency departments, which previously had some of the worst waiting times in the country.
Another concern about Medicare UCCs is fragmentation of care. 'Only 68% of patient presentations to Medicare UCCs resulted in an electronic discharge summary being sent to the GP,' said Wright. 'Better transitions of care are the key to preventing hospital admissions and readmissions and saving costs.'
Wadhwani, Adie, Wright, Cutler, Hespe, and Gardner reported having no relevant financial relationships.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dear Abby: My SIL is enabling her husband's alcoholism and I'm out of options
Dear Abby: My SIL is enabling her husband's alcoholism and I'm out of options

Yahoo

time42 minutes ago

  • Yahoo

Dear Abby: My SIL is enabling her husband's alcoholism and I'm out of options

DEAR ABBY: My sister-in-law is her alcoholic husband's enabler. He has health conditions that make walking difficult. He falls down often and can't make it to the bathroom. Being drunk all the time (he consumes a fifth of vodka every two days) also prevents him from getting the surgery he needs. My SIL buys his liquor for him. She says if she doesn't, he will drive himself, endangering others. She has tried talking with his doctors, friends, family, priest, and rehab facilities. He won't go or listen. Taking care of him is wearing her down. He needs a medical facility that also treats addiction. Desperate to help her, I took her to an Al-Anon meeting so she could get support, but she found it 'boring.' I realize this is out of my control, and I'm finding it hard to listen and sympathize when she complains. What now? — ENABLER'S SISTER-IN-LAW DEAR S.I.L.: Your sister-in-law definitely could use some help. While I have mentioned AA and Al-Anon often in my column, another support resource I have heard good things about is called SMART Recovery. It is a space where loved ones of those who are struggling with addiction can find understanding, support, and a plan to regain control of their own lives. She can locate a Family and Friends meeting by visiting If she gives it a try, she may feel more comfortable there. ** ** ** DEAR ABBY: I am a 60-year-old retired woman, happily married with a positive mindset. I am very active and stay current on world events. I have noticed over the past few years that many of my friends only want to talk about themselves. I was taught that a conversation should be an opportunity for both parties to engage in talking and listening, but now it seems like when we get together for a meal, they go on and on about themselves or people I don't know. Then, at the end of the meal, they'll finally throw in a 'How are you?' I find this extremely rude. I should be able to get a word in edgewise during a conversation. What can I do so these long-winded friends won't leave me frustrated? — LISTENING PATIENTLY IN NEW YORK DEAR LISTENING: Older people who talk only about themselves may do it because their 'universe' has shrunk, and they have little else to talk about. The next time you are in this situation, really listen to what those friends are saying. If I am right, spend less time with them and concentrate on enlarging your social circle to include folks with whom you have more in common. Dear Abby is written by Abigail Van Buren, also known as Jeanne Phillips, and was founded by her mother, Pauline Phillips. Contact Dear Abby at or P.O. Box 69440, Los Angeles, CA 90069. Solve the daily Crossword

Early Access to Weight Loss Jabs in NICE Diabetes Plan
Early Access to Weight Loss Jabs in NICE Diabetes Plan

Medscape

time44 minutes ago

  • Medscape

Early Access to Weight Loss Jabs in NICE Diabetes Plan

People with type 2 diabetes (T2D) in England could be offered earlier access to newer treatments, including weight loss jabs, under draft guidance from the National Institute for Health and Care Excellence (NICE). The guidance, described as the 'biggest shake-up in care for a decade', would see a shift from a one-size-fits-all approach to a focus on personalised treatment to prevent heart failure, heart attacks, and other serious complications. Expanded Use of SGLT-2 Inhibitors The draft guidance recommends expanding access to sodium-glucose co-transporter-2 (SGLT-2) inhibitors, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. Currently prescribed as a second-line option, SGLT-2 inhibitors would be available as a joint first-line treatment alongside metformin. They may also be used as monotherapy in patients intolerant to metformin. SGLT-2 inhibitors are once-daily tablets that selectively block the SGLT-2 cotransporter in the proximal renal tubule, responsible for reabsorbing about 90% of filtered glucose. This lowers the renal glucose threshold, increasing urinary glucose excretion and inducing mild osmotic diuresis. However, a 2024 NICE analysis of nearly 590,000 people with T2D in England found under-prescribing of these drugs, particularly among women, older adults, and Black patients. Only 20% of patients with atherosclerotic cardiovascular disease received SGLT-2 inhibitors, with prescribing rates declining in older age groups. NICE estimates that wider use of SGLT-2 inhibitors could save nearly 22,000 lives once uptake reaches 90%. Earlier Access to GLP-1 Agonists The draft guidance also recommends earlier use of glucagon-like peptide-1 (GLP-1) receptor agonists such as liraglutide or semaglutide. These drugs, previously reserved for later stages of disease, would be considered earlier in treatment for selected groups. NICE further supports wider adoption of digital health tools, including continuous glucose monitoring and community-based digital care. Personalised Treatment Approaches The guidance proposes tailored treatment strategies based on patient characteristics and comorbidities: Adults with cardiovascular disease should receive triple therapy (metformin, an SGLT-2 inhibitor, and a GLP-1 receptor agonist) Those with early-onset T2D (diagnosed before age 40) should receive dual therapy before considering a GLP-1 receptor agonist Patients with obesity or chronic kidney disease should have specific combinations based on their condition and kidney function, respectively. Adults with clinical frailty should start with metformin monotherapy. Professor Jonathan Benger, deputy chief executive and chief medical officer at NICE, said the draft guidance marks a 'significant evolution' in diabetes care. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes, and other serious complications before they occur,' he said. Burden of Diabetes in the UK Approximately 4.6 million people in the UK have diabetes, with 90% diagnosed with T2D. Diabetes UK estimates that a further 1.3 million may be undiagnosed. The condition costs the NHS £1 million per hour, with 60% of spending linked to complications. Each week, diabetes contributes to more than 930 strokes, 660 heart attacks, and nearly 2990 cases of heart failure. Douglas Twenefour, head of clinical at Diabetes UK, welcomed the draft guidance. 'The majority of people with T2D are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications,' he said. 'Tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease.' Waqaar Shah, a GP partner at Chatfield Health Care in London and chair of the NICE guideline committee, said that these recommendations 'could help reduce health inequalities while providing better outcomes for everyone'. Implementation and Safety The draft guidance remains open for public consultation until 2 October. NICE will review feedback before publishing final recommendations. The guidance aims to promote equitable access to recommended therapies, supported by local training initiatives. Healthcare professionals have also stressed the need for safe prescribing of SGLT-2 inhibitors, which carry risks including diabetic ketoacidosis (DKA). Before starting treatment, providers should assess whether patients have previously experienced DKA, have acute illness, or follow very low-carbohydrate or ketogenic diets.

Curewell Capital Closes Oversubscribed Inaugural Fund at $535 Million
Curewell Capital Closes Oversubscribed Inaugural Fund at $535 Million

Yahoo

timean hour ago

  • Yahoo

Curewell Capital Closes Oversubscribed Inaugural Fund at $535 Million

LOS ANGELES, August 20, 2025--(BUSINESS WIRE)--Curewell Capital ("Curewell"), a private equity firm focused on building industry-leading middle-market healthcare companies, announced the closing of Curewell Capital I, LP (together with its related vehicles, the "Fund") at its hard cap of $535 million. The inaugural Fund was raised in a single closing and completed less than five months after launch. Curewell secured commitments from a diverse group of global institutional investors, comprised of leading endowments, foundations, pensions, insurance companies, consultants, family offices, and industry executives. Curewell is led by Michael Dal Bello and Ceron Rhee, who have worked together for nearly two decades, including their shared tenures at Blackstone and more recently at Pritzker Private Capital, where they led the healthcare investment practice. The Fund builds on the team's established strategy of acquiring leading U.S. healthcare businesses across healthcare services, pharmaceutical services, medical devices, and healthcare technology. Curewell seeks to partner with experienced founders and management teams leading extraordinary healthcare companies to help accelerate growth and operational performance. "We are grateful for the trust and support of an exceptional group of investors. We are further honored to work with founders, owners, and management teams who share our vision of increasing access to healthcare, lowering overall system costs, and enhancing quality of care. We look forward to building lasting value together," said Michael Dal Bello, Co-Founder and Partner. "This fund represents our next chapter in partnering with accomplished teams advancing innovation and transformation in healthcare," added Ceron Rhee, Co-Founder and Partner. "We are seeing strong secular tailwinds across our key areas of focus, providing meaningful opportunities for companies to improve outcomes and drive efficiencies throughout the U.S. healthcare system." Probitas Partners acted as the exclusive placement advisor for the Fund, and Kirkland & Ellis LLP acted as fund counsel. About Curewell Capital Curewell is a Los Angeles–based private equity firm focused on building industry-leading middle-market healthcare companies headquartered in North America. Drawing upon decades of investment and operating experience across healthcare services, pharmaceutical services, medical devices, and healthcare technology, Curewell seeks to partner with founders and management teams leading premier companies that improve patient outcomes, create efficiencies, and foster innovation. Curewell's proprietary GRO™ framework is tailored to each company to drive long-term value through growth and operational excellence. For additional information, please visit View source version on Contacts Curewell Capitalinfo@ (310) 361-1510 Error in retrieving data Sign in to access your portfolio Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store